^
Association details:
| Biomarker: | SLFN11 underexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
Published date:
05/11/2023
Excerpt:
U937- and HEL-SLFN11KO cells were incubated with increasing concentrations of cytarabine (AraC)... In contrast, SLFN11KO cells and control cells were equally sensitive to AZA and DAC, suggesting that HMAsmay be preferable to AraC for patients with SLFN11-low AML...Low SLFN11 levels predict poor response to standard chemotherapy agents (i.e. AraC) in AML cells, suggesting that SLFN11 may prove to be an important predictive biomarker for AML patients.
